Drug Discovery Informatics Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Drug discovery informatics and development is an extremely complex process that involves generation of large volumes of data. At present the market for drug discovery informatics is largely unmet. The existing approaches to gather information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. Nonetheless, the world on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are experiencing a paradigm shift. The demands of this industry are well defined: huge amounts of data are produced using various innovative technologies and the restraint is searching, integrating, and accessing this data.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/224

Additionally, the inclination is to make important development decisions in the early life cycle of the discovery process. It has become crucial to take care of these issues with the vast amount of data available from ongoing projects and also from early efforts of drug development. The future of drug discovery informatics will be the assimilation of distributed and heterogeneous data. Domain specific data mining and data integration such as genomic and chemical data will continue to offer significant opportunities for drug discovery informatics. Procurement and management of graphical, textual and undefined data are some of the challenges in this field. However, these will become a vital part of data searching as well as building knowledge and information-bases. These factors will eventually lead to the growth of the data discovery informatics market during the forecast period.

Increasing chronic illnesses such as cancer, cardiovascular diseases (CVD), and diabetes mellitus is the chief concern for healthcare professionals and government organizations around the globe. The U.S. government in association with President’s Council of Advisors on Science and Technology (PCAST) has taken initiatives intended to improve financial stimulus to induce modernization in the pharmaceutical industry, which will drive the overall market for drug discovery informatics.  Furthermore, collaborations amongst pharmaceutical companies have given rise to infusion of money and sharing of technologies amongst them, which has enabled these companies to develop local as well as global products.

Ask for Discount before buying the Report@ https://www.coherentmarketinsights.com/insight/request-discount/224

Drug Discovery Informatics market Taxonomy

On the basis of mode, the global drug discovery informatics market is classified into:

• In-House Informatics
• Outsourced Informatics

On the basis of service segment, the global market is classified into:

• Sequence Analysis Platforms
• Molecular Modelling
• Docking
• Clinical Trial Data Management
• Others

On the basis of product segment, the global market is classified into:

• Discovery Informatics
• Identification & Validation Informatics Assay Development Informatics
• Lead Generation Informatics
• Development Informatics
• Lead Optimization
• FHD Preparation
• Phase IA Informatics
• Phase IB/2 Informatics

Advent of technology and the increasing number of clinical trials will drive the overall drug discovery informatics market

With the advent of technology, innovative cloud-based and analytics technologies, storage and analysis of large amount of data is now possible at a lower cost. For example, Infosys popularized a cloud-based application to accelerate the management of data services for clinical trials. This in turn is likely to drive the whole drug design procedure. Infosys has been working in partnership with various clinical trial organizations and pharmaceutical companies to master the application and to provide easy access and management of data.

The facilities that are offered can be outsourced to other organizations or can be used in-house via licensed solutions. In-house informatics segment holds a significant market share in the present scenario owing to the presence of information technology platforms in most of the companies. However, outsourced informatics segment is likely to grow at a considerable pace during the forecast period as the key industry players are opting for collaborations with the IT providers to increase their access to the tools and databases for clinical drug discovery.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/drug-discovery-informatics-market-224

Europe accounted for the major market share in the drug discovery informatics market. Some of the major factors for the same are rise in the clinical discovery ventures as well as various activities carried out by research institutes, universities, and companies. Nonetheless, Asia Pacific is predicted to grow at a significant pace during the forecast period owing to high prospect of drug nanotechnology sector in this region as well as advancements in research software. 

Some of the key players operating in the global drug discovery informatics market are Albany Molecular Research, GVK Biosciences, Infosys, Certara, ChemAxon, Jubilant Biosys, DiscoverX, Novo Informatics, Charles River Laboratories, Boehringer Ingelheim GmbH, and Selvita.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Cosmeceuticals Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Cosmetics and pharmaceuticals together make cosmeceuticals. A cosmeceutical has the active potential ingredient to bring about visible changes to the skin, and these changes are backed by clinical indication. Cosmeceutical products are marketed as cosmetics, though they comprise biologically active ingredients that provide medicinal or drug-like properties. For example, anti-wrinkle skin creams includes ingredients such as alpha lipoic acid and dimethylaminoethanol and creams containing cellular replacement serum that claim to have anti-aging properties. The cosmetic industry coined the term, though the US FDA does not recognize the term cosmeceuticals.

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/221

A cosmetic product will effectively maintain skin quality by providing somewhat temporary results. It may contain active ingredients, though concentration of these actives is usually negligible. A cosmeceutical product differs from such cosmetic products, as it has a high concentration of active ingredients and usually comprises various active ingredients. This formulation can bring about visible changes to the skin making it a results-focused product. Cosmeceutical products are restricted to professional skin care vendors where a consultation can be provided.

The cosmeceuticals market includes a large category of cosmetic products that have drug-like benefits. Varity of cosmeceuticals products available in the market include lip care, skincare, tooth whitening, hair care, injectable and others. The skincare segment holds a prominent share and is followed by hair care segment. In the skincare segment, anti-ageing products are most popular and hence, gross maximum revenue.

Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/221

Cosmeceuticals Market Outlook: Developed Regions Still Offer Lucrative Growth Opportunities

The global cosmeceuticals market is expected to witness strong growth over the forecast period, owing to rising consumer awareness regarding the benefits of cosmeceuticals. Among all regions, North America is projected to contribute the highest market share, followed by Europe throughout the forecast period. The well-developed healthcare infrastructure and high per capita income in the U.S., drives growth of the cosmeceuticals market size. The Asia Pacific market in cosmeceuticals is projected witness highest growth during the forecast period, due to large middle-aged population (the largest demographic group in the market) and increasing disposable income in this region. In Asia Pacific region, Japan is expected to contribute largest market share and to exhibit with highest growth, followed by China.

Increasing inclination towards maintaining personal aesthetics and increasing number of urban population together with rising consumer awareness related to benefits of cosmeceuticals

Integration of advanced technologies such as nanotechnology, plant stem cell technology, and the development of new active ingredients are spurring growth of the global cosmeceuticals market. Large middle age population and baby boomer generation are inclined towards maintaining their personal aesthetic appeal, in turn fueling growth of the global cosmeceuticals industry. Furthermore, development of new active ingredients will create opportunities for global market. A major factor that restraints growth of the cosmeceuticals market is growing consumer awareness related to harmful effects of ingredients used in cosmeceuticals.

In cosmeceuticals, only Federal Trade Commission (FTC) works to scrutinise any advertised claims of pharmaceutical products or scientific validity. Opportunities in cosmeceutical market development are those that provide protection of skin from radiation and also oxidant damage by non-irritating ingredients which improve skin appearance.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/cosmeceuticals-market-221

Cosmeceuticals Market Taxonomy

On the basis of product type, the cosmeceuticals market is classified into:

• Skin Care
• Hair Care
• Injectable
• Cosmeceuticals Products

On the basis of ingredient, the cosmeceuticals market is classified into:

• Antioxidants
• Proteins
• Peptides
• Botanicals
• Moisturizers

Key players operating in the global cosmeceutical market include Croda International Plc, Bayer, Procter & Gamble, Beiersdor, Johnson & Johnson, Shiseido, Elementis, Unilever, L'Oréal, and Avon.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Personalized Gene Therapy Treatments for Cancer Market - Industry Analysis, Trends and Forecast to 2024

Gene therapy involves insertion of genetic material into cells of the patients to provide them a new function or to restore the missing or inappropriate functioning of the cells due to cancer or gene mutations. Scientists have created personalized medicines that are used to learn about a person’s genetic makeup and untangle the biologic nature of the patient’s cancerous cells for carrying out such therapies. Depending on the type of therapy, personalized gene therapy treatments for cancer market is differentiated into two segments which are as follows:

• Targeted treatments
• Pharmacogenomics

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/60

On the basis of application, the personalized gene therapy treatments for cancer market is analyzed into:

• Breast Cancer
• Leukemia
• Head & Neck Cancer
• Prostate Cancer
• Pancreatic Cancer
• Leukemia Cancer
• Melanoma
• Ovarian Cancer
• Brain Cancer
• Colorectal Cancer
• Lung Cancer
• Liver Cancer
• Bladder Cancer
• Lymphoma

Personalized Gene Therapy Treatments for Cancer Market Potential Applications

Targeted treatments are focused on cancer specific genes, tissues or the protein environment that contribute towards the cancer survival and growth. Researchers identify new targeted cells and develop and test new drugs and medications for such targets as per patient needs. In targeted treatments, the tumor cells themselves are targeted to cure cancer. Breast cancer, gastrointestinal stromal tumor, colorectal cancer, kidney cancer, melanoma, lung cancer, brain cancer, multiple myeloma, certain childhood cancers and lymphoma, and leukemia are the common types of cancers for which targeted treatments are applied.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/personalized-gene-therapy-treatments-for-cancer-market-60

Pharmacogenomics, on the other hand, affect the processes occurring in the body and drug responses. The difference in the processes influences the safety and efficacy of a drug. The basic principle behind the treatment is to activate the immune system cells that could attack and destroy the cancerous cells. Moreover, in this case, if the patients’ body does not respond to a medication, the drugs stay in the blood stream for longer period of time and may cause severe side effects. Therefore, this type of treatment carries a risk of reaction of drug from person to person, providing targeted treatment a preference over pharmacogenomics.

Personalized gene therapy treatments for cancer market involves evaluation of the developed drugs through clinical trials. Government support and funding and the advantages of personalized gene therapy over other treatment options such as chemotherapy and surgery are the major factors which are projected to drive growth of personalized gene therapy treatments for cancer market. For instance, the U.S. government has set up the MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy in Texas to support preclinical research and clinical trials for targeted therapy for particular genes. Such government initiatives are encouraging researchers to develop more effective personalized gene therapy treatments for different types of cancer, thus boosting growth of the cancer personalized gene therapy treatments market. However, high costs associated with these treatments and the unavailability of personalized gene therapy treatment for some types of cancers is the major factor that is projected to restrain growth of the personalized gene therapy treatments for cancer market.

Geographically, the personalized gene therapy treatments for cancer market has been analyzed into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The major players in the customized gene therapy treatments for cancer market include Amgen, Inc., SynerGene Therapeutics, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., Cold Genesys, Inc., Takara Bio, Inc., Bellicum Pharmaceuticals, Inc., Ziopharm Oncology, Inc., OncoSec Medical, Inc., Sevion Therapeutics, Inc., and Burzynski Clinic.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tissue Transplantation Products and Services Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Chronic diseases often lead to catastrophic damage to vital organs. This damage is usually irreversible and leads to lifetime dependency on medicines. Under such severe conditions, transplants remain the mainstay for restoration of healthy life. Globally, there has been a surge in tissue transplant with advances in medical biotechnology. Tissue transplantation and services market has seen an increased demand especially from high income countries. Higher prevalence of diseases such as diabetes, cancer, cardiovascular diseases, renal diseases and Alzheimer’s disease have post a threat of irreversible tissue damage to a large population globally. According to an article published in the Journal of Diabetes Care, in 2010, prevalence of diabetes related end stage renal disease escalated from 17,727 in 1990 to 48,215 in 2006 in the U.S. Large percentage of cancer patients need to undergo bone marrow transplant. Bone marrow and peripheral blood stem cell transplantation procedures are essential in restoration of stem cells that have been destroyed due to high doses of chemotherapy and radiation treatment. According to World Health Organization, globally, over 14 million new cases and 8.2 million cancer related deaths were recorded in 2012. Thus, a large target population base exists for companies in the global tissue transplantation products and services market.

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/76

Global Tissue Transplantation Market Segment

• Based on the Tissue Type
• Cornea
• Heart Valve
• Skin Grafts
• Vascular Grafts
• Bone Marrow
• Bone Grafts

Tissue transplantation products mainly include processed stem cells, which involve multiplication and differentiation as per patient requirements. Government standards and guidelines have been set for storage and processing of stem cells for therapeutic purposes. Some of the government as well as private service providers include NHS Blood and Transplant, Tissue Services, U.K., LifeCell Corporation, Mid-America Transplant Services, Australian Red Cross Blood Service. These institutes provide storage and processing services to transplant patients. Bone marrow storage banks have been of prime importance, as they help in finding appropriate match for transplant.

Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/76

Autologous stem cell transplant has become convenient mainly due to advent of induced pluripotent stem cells (iPSC). Scientists are trying to develop organs from human induced pluripotent stem cells (iPSCs). An article published in Nature in 2013, reports the generation of a functional human organ from pluripotent stem cells. This technique surpasses the risk of immunosuppression and graft-vs-host disease associated with bone marrow transplant. Although expensive, the chances of success are higher in case of iPSC transplant procedures. Currently, the market for tissue transplant products and services is mainly driven by various advancements in iPSC methods.

As the technology is in its nascent stage of development, immense scope exists for players to enter the market. However, changing regulatory policies, and practice of un-approved tissue transplantation, especially in South-East Asia Pacific countries has impeded the growth of tissue transplant products and services market. In response to increasing demand, government funding is also expected to increase for more research in tissue transplant across the globe. As companies receive approvals for application of tissue transplant, market for service providers is expected to increase drastically. As more safety standards are established, the global tissue transplantation products and services market would enter in its growth phase. The U.S., Japan, and major European countries are preferred targets for market entry. 

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/tissue-transplantation-products-and-services-market-76

Key Players: Abbott, Biomet, CryoLife, Inc., Arthrex, Exactech, Inc., Celera, Folio Biosciences, Köhler Chemie, Bristol-Myers, LifeCell Corporation, Centacor and Novartis.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Automated Breast Ultrasound Systems Market By, Product Type, End-use, Application, Geography - Trends & Forecast to 2024

Automated Breast Ultrasound Systems – The Future of Breast Screening

Breast cancer is the most commonly diagnosed type of cancer and the second leading cause of death among women, as evident from stats revealed by the National Breast Cancer Foundation. Growing awareness of breast cancer has increased number of women undergoing breast screening and in turn would propel demand for automated breast ultrasound systems (ABUS) in hospitals and diagnostic centers. ABUS enables physicians to screen women, especially with denser breasts and provides superior image quality, thus providing them a competitive edge over handheld ultrasound systems (HHUS)

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/78

The global automated breast ultrasound systems market was valued at US$ 236.5 million in 2015 and is expected to expand at a CAGR of 21.6% during the forecast period (2016 – 2024).

ABUS are primarily used for screening purpose in adjunct to mammography

ABUS are approved by the U.S. FDA for screening in conjunction with mammography for dense breasts. Radiologists are inclined towards adoption of ABUS as they provide high quality 3D images. Surgeons are adopting this system for pre-operative evaluation of breast to accurately identify the tumor size and location. HHUS are mainly preferred for preoperative evaluation as compared to ABUS, due to high cost associated with ABUS and lack of skilled radiologists to operate the ABUS system during the crucial preoperative period.

High prevalence of breast cancer and awareness campaigns driving demand for ABUS in developed countries

Factors attributable to the growth of ABUS in North America and European markets include increased patient awareness, high uptake of early breast screening, and availability of funds to install relatively expensive ABUS.

Ask for Discount before buying the Report: https://www.coherentmarketinsights.com/insight/request-discount/78

• According to the World Health Organization (WHO), 232,924 new cases of breast cancer were diagnosed in 2013. Moreover, the American Cancer Society estimates that until 2016 there are over 2.8 million breast cancer survivors in the U.S.
• According to the Cancer Research UK, the incidence rate of breast cancer in the U.K is expected to rise by 2% from 2014 to 2035
• Public Health England launched a campaign called ‘Be Clear on Cancer’ (2015) to raise breast cancer awareness among women over 70 years. Moreover, research and development in the field is encouraged through the Breast Cancer Now Catalyst Programme (2016).
• High prevalence coupled with government awareness drives are driving demand for ABUS in the U.S. and U.K.

Increasing awareness programs related to breast cancer driving demand in Asia-Pacific region

Asia-Pacific possess immense revenue potential for the growth of ABUS market. Demand for ABUS in Asia-Pacific in terms of volume is expected to increase at a CAGR of 24.4% during 2016 – 2024. Lack of awareness had deterred the uptake of early breast screening until various cognizance initiatives were undertaken by ABUS manufacturers and non-profit and regional cancer organizations. Some noteworthy initiatives include The Pink Initiative organization in India, Breast Cancer Initiative East Africa Inc. and Pink Ribbon Breakfast initiative by Cancer Australia. Moreover, denser breast tissues in the Chinese population is driving demand for ABUS in China at a rapid pace.

Browse the full Automated Breast Ultrasound Systems (ABUS) Market Report At: https://www.coherentmarketinsights.com/market-insight/automated-breast-ultrasound-systems-market-78

Automated breast ultrasound systems manufacturers are following inorganic strategies to increase their footprint

Inorganic growth roadmap is the key strategy followed by market leaders. For instance, GE Healthcare acquired U-Systems, Inc. in 2014 to expand their breast care innovations portfolio. Philips partnered with SonoCine, Inc. in 2014 to provide ABUS imaging for its ultrasound systems. Hitachi Aloka Medical America, Inc. entered into a strategic alliance with iVu Imaging Corporation in 2014, gaining exclusive distribution rights for iVu’s SOFIA (ABUS) system in North America.  This agreement helped iVu Imaging Corporation to get access to the expanded channel and also helped both the companies to leverage the technical expertise of the other which further improved the performance of SOFIA.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Global Blood Processing Devices & Consumables Market, By Product Type - Trends, Size, and Forecast 2024

Blood Processing Devices and Consumables – One Pint Saves Three Lives

Blood collected from donors can be stored and transfused in an unmodified state, referred to as whole blood transfusion. However, if processed, the collected blood can be of use to more than one patient. According to the World Health Organization (WHO) 2016 estimates, only 43% of the blood collected in low-income countries are separated into different components such as plasma, red cell concentrates, and platelet concentrates. The rate is much higher (96%) in high income countries such as Argentina, Canada, U.S., Germany, Singapore, U.K., and France. Lack of adequate test kits, blood processing devices and infrastructure are some of the factors responsible for low rate of blood processing in low-income countries.

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/83

The global blood processing devices and consumables market was valued at US$ 27,845.1 million in 2015 and is expected to expand at a CAGR of 5.9% during the forecast period: 2016 – 2024.

Increasing number of blood transfusion procedures making blood processing a necessity

Blood transfusion is a process required to make up for the lost blood during a surgery or due to an injury or a disease. According to the American National Red Cross, a humanitarian organization, around 21 million blood components are transfused every year in the U.S. Blood transfusion is a frequent process in sickle cell patients. The sickle cell disease affects 90,000 to 100,000 people in the U.S., as per the American National Red Cross.

Demand for blood processing devices and consumables is growing rapidly with establishment of new hospitals and blood banks, and increasing number of blood transfusion procedures. Asia Pacific is one of the most lucrative markets for blood processing devices and consumables.  According to the Friends2support organization, a non-profit organization allowing patient access to blood donors, nearly 30 million blood components are transfused every year in India.

Ask for Discount before buying the Report@ https://www.coherentmarketinsights.com/insight/request-discount/83

Lack of blood processing infrastructure in low-income countries

According to WHO, 16 countries across the globe are unable to screen the donated blood for one or more than one infections. WHO identified irregular supply of test kits is the factor attributed to this shortage. The Blood and Transfusion Safety program of WHO supports countries in developing national blood systems to ensure quality blood processing and transfusion practices.

High capital investment and steep operational costs are the factors restraining emerging economies such as India, Brazil, China, and Indonesia to adopt the new blood processing technology. 

Development of national blood policy recommended by WHO

According to the 2016 World Health Organization (WHO) statistics, around 112.5 million units of blood donations are collected every year globally. However, only a few get access to blood on time. Several patients in need of blood transfusion are deprived of blood for their treatment. The WHO therefore recommend having a national blood policy to have centralized control for blood collection, testing, storage, processing, and distribution. According to the WHO, in 2013, 73% of 167 countries worldwide had a national blood policy.

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/market-insight/blood-processing-devices-and-consumables-market-83

Low blood donation rate impacts the demand for blood processing and consumables market negatively. Therefore, improved storage and processing facilities of the donated blood coupled with increase in access to blood and its components will generate demand for blood processing and consumables

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Growing Burden of Non-communicable Diseases to Underpin Rise of Clinical Laboratory Services Market to Mid US$ 300 Billion Level by 2024

The Global Clinical Laboratory Services Market was valued US$ 168.9 billion in 2015 and is projected to expand at a CAGR of 7.3% during the forecast period (2016-2024), as analyzed by Coherent Market Insights in a detailed report about the same. Increasing health consciousness leading to higher preventive measures, especially in Asia Pacific region, would be a major factor for increasing demand of the clinical laboratory services market. Increasing insurance coverage is further propelling adoption of diagnostic testing and in turn favors growth of clinical laboratory services market.

Download Exclusive PDF Brochure of This Report: https://www.coherentmarketinsights.com/insight/request-sample/87

In order to capitalize on this highly lucrative opportunity, clinical laboratory service providers such as Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Inc., Spectra Laboratories, Sonic Healthcare Limited, and Charles River Laboratories are offering additional services such as web-based booking of test/service and free home pick-up of test samples, complementing regular packages for health check-ups. Charles River Laboratories International, Inc., analyzes samples for metabolic disorders, bone therapy, diabetes and oncology. Globally too, clinical laboratories receive large volumes of samples for analyzing metabolic disorders. The market for clinical chemistry test types is therefore positioned on a strong growth trajectory.

Increasing competition among clinical laboratory service providers in turn is leading to rampant increase in industry consolidation and vertical/horizontal integration. Companies are focusing on establishing regional supremacy in turn improving the dynamics of clinical laboratory services market.

For instance, Laboratory Corporation of America Holdings (LabCorp) acquired Sequenom, Inc. in July 2016, subsequently becoming the leader in non-invasive prenatal testing (NIPT) for reproductive health. The company continues its inorganic growth roadmap and in October 2016, it acquired ClearPath Diagnostics, a leading clinical laboratory service provider in the Northeastern region of the U.S.

Ask for Discount before buying the Report@ https://www.coherentmarketinsights.com/insight/request-discount/87

In November 2016, Sonic Healthcare Limited increased its ownership stake in GLP Systems from 25% to 80%. GLP Systems, a Germany-based company, developed an innovative laboratory automation technology that enables seamless and automated transportation of specimen tubes between storage, work areas, and diagnostic machines.

Furthermore, Sonic Healthcare Limited also expanded its presence in Germany by acquiring Staber Laboratory Group based in Munich, Germany, in November 2016. The Staber Group has three hub laboratories and 14 regional, specialty and hospital labs in Germany, making it one of the leading players in the country.

Increasing incidence of infectious diseases and the growing burden of non-communicable diseases is in turn driving demand for clinical tests. This is influencing clinical laboratory service providers to increase their functional capabilities to cater to the growing needs of patients. As mentioned by Quest Diagnostics, Inc., around 70% of the medical decision are based on lab results. In addition, genetic and cytology testing is increasing that enable better diagnosis of cancer. This is expected to proliferate demand and spur growth for clinical laboratory services market in emerging economies such as China and India. Core Diagnostics, Metropolis, SRL Diagnostics and Dr. Lal Pathlabs are few major diagnostic service providers in India expanding at a rapid pace.

Clinical laboratory service providers are thus, upgrading their processes and technologies to improve efficiency. Therefore, equipment manufacturers such as Abbott Laboratories, Roche and ThermoFisher Scientific also need to develop products catering to this evolving market. Seamless integration of equipment manufacturer and service provider technologies would be a great boost for the global clinical laboratory services market.

Key takeaways of the market:

• The global clinical laboratory services market is estimated to be valued at US$ 192.3 billion in 2017. Growing aging population and increasing incidence of infectious diseases, cardiac disorders, stroke, and liver disorders are factors attributed to growing number of patients visiting clinical laboratories to undergo preventive tests

Browse the full Clinical Laboratory Services Market report at: https://www.coherentmarketinsights.com/market-insight/clinical-laboratory-services-market-87

• Clinical chemistry test was the dominant segment in the global clinical laboratory services market, accounting for more than 40% of total revenue share in 2015. Clinical chemistry test includes testing of blood and urine samples in the patients as an initial step to diagnose a disease or preexisting health condition.
• Among service providers, the hospital-based clinical laboratories segment generated the highest revenue in 2015. This is owing to availability of better diagnostic devices and services in hospitals as compared to other healthcare service providers.
• However, the services offered by standalone clinical laboratories are improving rapidly, wherein accessibility to patients has increased
• The clinical laboratory services market is expected to gain significant growth traction in Asia Pacific and Latin America, mainly attributed to high prevalence of infectious and non-communicable diseases, increasing health concerns, and new diagnostic laboratories being established to cater to the growing needs of patient for health check-ups
• Consolidation is the key trend observed in order to cement the market presence and sustain the customer base - LabCorp acquired Sequenom, Inc in July 2016, and ClearPath Diagnostics in October 2016

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Antidiabetic Biosimilars Market by Product, End-user and Geography - Trends and Analysis till 2024

Antidiabetic biosimilars market overview

Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to patients as the reference product.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/92

Patent expiries to drive growth of the global antidiabetic biosimilars market

The global antidiabetic biosimilars market is driven by increasing number of diabetes mellitus patients. According to World Health Organization (WHO) the number of people suffering from diabetes stood at 422 million in 2014. The global prevalence of diabetes among adults above 18 years increased to 8.5% in 2014 from 4.7% in 1980. Increasing incidence of lifestyle disorders such as obesity, increases the risk of diabetes and in turn drives growth of the antidiabetic biosimilars market. In June 2014, the European Medicines Agency authorized the first biosimilar of insulin Glargine, Abasaglar from Eli Lilly and Company and Boehringer Ingelhim International Gmbh, for treatment of diabetes mellitus. The biosimilar received U.S. FDA approval in 2016, which would fuel growth of the antidiabetic biosimilars market.

Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/92

Furthermore patent expiry of insulin aspart and insulin lispro is projected to propel growth of antidiabetic biosimilars market. Biosimilar insulin have potential to reduce diabetes treatment costs, increase accessibility of insulin treatment and expand the number of insulin brands. Some antidiabetic biosimilars which are approved or are in approval process include:

Product	Company	Status
SB9/MK-1293	Samsung Bioepis/Merck	Submitted to FDA for approval in August 2016 and to EMA in December 2015. Approved by EMA in November 2016.
Abasaglar/ Basaglar/ LY2963016	Eli Lilly/Boehringer Ingelheim	Approved by EMA in September 2014, by US FDA in August 2014, bu Australia in May 2015 and by Japan in January 2015
Glaritus	Wockhardt	‘Similar biologic’ launched in India in March 2009
Basalog	Biocon/Mylan	‘Similar biologic’ launched in India in 2009. Received approval in Japan in March 2016 and launched in July 2016. EMA regulatory submission in November 2016.

Constraints for growth of the antidiabetic biosimilars market

Biosimilars would have to face stringent regulatory requirements that would focus on their production before entering into major markets such as the U.S. While biosimilars have marked successful entry in the European markets, entry in the U.S. market is still a challenge due to stringent regulatory norms. Furthermore, biosimilars would need to gain favorable reimbursement to gain market traction.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/antidiabetic-biosimilars-market-92

Increasing number of diabetes patients driving the antidiabetic biosimilars market globally

Increasing incidence of diabetes, complexities in alternative diabetic therapies, and government incentives for introduction of low cost therapies are collectively creating a conducive environment for growth of the market. According to the International Diabetes Federation (IDF), there were around 59.8 million diabetic patients in Europe in 2015. The market for antidiabetic biosimilar is expected to be high in near future in Asia Pacific due to increase in research activities related to antidiabetic products and supportive government funding.  North America region is projected to represent a lucrative market for antidiabetic biosimilar in the near future, as prevalence of diabetes is increasing in this region. According to the International Diabetes Federation, in 2015, over 29.1 million people in the U.S. suffered from diabetes.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Elbow Lesion Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Elbow Lesion Market Overview

An elbow joint is made up of three bones namely, humerus, radius, and ulna. There are several important muscles that cross the elbow joint giving the strength and movement. Elbow disorder may involve arm muscles, elbow ligaments, tendons, and bones in the arm. Chronic pain of extensors at the elbow is known as tennis elbow. Over use of elbow and sports injuries can cause various elbow conditions. Golfers, Baseball pitchers, tennis players, and boxers are most susceptible to elbow disorders. Different types of elbow disorders include medial epicondylitis, lateral epicondylitis, olecranon bursitis, osteoarthritis, dislocation or fracture of the elbow, ligaments strains and sprains, and osteochondritis dissecans. Elbow disorders can be diagnosed by physical examination and studying patient history, x-rays, computerized tomography scan, magnetic resonance imaging, electromyography, and biopsy of bursa fluid.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/96

Increasing geriatric population highly prone to bone injury and rising number of sports related injuries driving growth of the elbow lesion market

Rise in prevalence of elbow tendon, increasing incidence of elbow joint pain, and growth in healthcare investment are factors driving growth of the global market for elbow lesion. According to the National Institute for Health and Care Excellence (NICE) tennis elbow was prevalent in 1%-3% of UK population in 2012. It has been observed that people above 60 years are more afflicted with elbow pain. Therefore, rapidly growing geriatric population and increasing incidence of arm fracture due to accidents are expected to drive growth of the elbow lesion market in the near future.

Platelet-rich plasma – An effective antidote for tennis elbow

The elbow lesion market is classified on the basis of treatment methods into surgical and non-surgical therapies. Arthroscopic surgery and open surgery are types of surgical therapies performed. Non-surgical therapies comprise drugs and physical therapy.

Ask for Discount before buying the Report@ https://www.coherentmarketinsights.com/insight/request-discount/96

Various non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen, aspirin, and cortisone are administered to control pain. Other drugs used for treatment of elbow pain include botulinum toxin and hyaluronate propelling growth of the elbow lesion market. Platelet-rich plasma (PRP), a novel technique, is being preferred for treatment of tennis elbow. It involves taking a blood sample from the patient, which is then treated to increase the number of platelets compared with other cells in the sample. Physical therapies such as muscle stimulation and ice massage are used to expedite the healing process.

Rising number of sports injuries drives growth of the elbow lesion market in North America

Increasing number of sports events and competitions in the U.S, increasing patient awareness, good medical facilities, and favorable reimbursement policies are factors fueling growth of the elbow lesion market. Elbow injuries are considered to be an expected consequence of throwing sports.  According to a study published in Orthopaedic Journal of Sports Medicine in 2013, 30% of baseball players will have elbow pain every year, and nearly 60% of players with elbow pain will show radiographic abnormalities. The elbow lesion market in emerging markets such as India, China, Russia, and Brazil is growing due to increase in number of sports injuries in these regions, use of advanced technology in diagnosis, and improving medical facilities offered by government and private companies.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/elbow-lesion-market-96

Key players engaged in the elbow lesion market

Key manufacturers of elbow braces for athletes include Mueller Sports Medicine and Professional Orthopedic Products, among others.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.